Back to Search Start Over

An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders.

Authors :
Breitborde NJK
Keller-Hamilton B
Moe AM
Pine JG
Nelson N
Weiss D
Hogan T
Quisenberry A
Teferra A
Ferketich AK
Source :
Journal of smoking cessation [J Smok Cessat] 2021 Jul 27; Vol. 2021, pp. 6617716. Date of Electronic Publication: 2021 Jul 27 (Print Publication: 2021).
Publication Year :
2021

Abstract

Introduction: Individuals with psychotic-spectrum disorders may smoke due to the ameliorating effect of nicotine on the cognitive deficits that accompany these illnesses. Metacognitive remediation therapy (MCR) has been shown to produce improvements in cognitive functioning among individuals with psychotic-spectrum disorders and provides a foundation for a novel smoking cessation intervention for this population.<br />Aims: To complete an open investigation of pharmacotherapy and a modified version of MCR [MCR to Quit (MCR-Q)] in promoting smoking cessation among individuals with psychotic-spectrum disorders.<br />Methods: Forty-nine individuals with a psychotic-spectrum disorder and who currently smoke cigarettes participated in MCR-Q while also receiving evidence-based smoking cessation pharmacotherapy. Tobacco use was assessed as follows: (i) prior to MCR-Q, (ii) immediately after completing MCR-Q, and (iii) six weeks after completion of MCR-Q.<br />Results: / Findings . During participation in MCR-Q, nearly 80% of participants made a 24-hour quit attempt. Following the completion of MCR-Q, participants experienced reductions in level of nicotine dependency and exhaled carbon monoxide, with reductions in nicotine dependency sustained six weeks after completion of MCR-Q. Over the course of their participation in MCR-Q, participants reported strong therapeutic alliance with their MCR-Q therapist and high levels of intrinsic motivation with regard to completing MCR-Q exercises.<br />Conclusions: The results from the current study suggest cautious optimism with regard to the use of MCR-Q in combination with medication for individuals with psychotic-spectrum disorders who want to quit smoking.<br />Competing Interests: Drs. Breitborde and Moe have received salary support with regard to trainings for metacognitive remediation therapy that were provided for activities not related to the current study.<br /> (Copyright © 2021 Nicholas J. K. Breitborde et al.)

Details

Language :
English
ISSN :
1834-2612
Volume :
2021
Database :
MEDLINE
Journal :
Journal of smoking cessation
Publication Type :
Academic Journal
Accession number :
34429783
Full Text :
https://doi.org/10.1155/2021/6617716